KR20240099142A - 병용 요법 - Google Patents

병용 요법 Download PDF

Info

Publication number
KR20240099142A
KR20240099142A KR1020247010022A KR20247010022A KR20240099142A KR 20240099142 A KR20240099142 A KR 20240099142A KR 1020247010022 A KR1020247010022 A KR 1020247010022A KR 20247010022 A KR20247010022 A KR 20247010022A KR 20240099142 A KR20240099142 A KR 20240099142A
Authority
KR
South Korea
Prior art keywords
agonist
glp
administered
receptor antibody
actrii receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247010022A
Other languages
English (en)
Korean (ko)
Inventor
로이드 벨 클릭스타인
마티아스 마하체크
Original Assignee
버사니스 바이오, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 버사니스 바이오, 인크. filed Critical 버사니스 바이오, 인크.
Publication of KR20240099142A publication Critical patent/KR20240099142A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020247010022A 2021-08-27 2022-08-26 병용 요법 Pending KR20240099142A (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163238068P 2021-08-27 2021-08-27
US63/238,068 2021-08-27
US202263301012P 2022-01-19 2022-01-19
US63/301,012 2022-01-19
US202263333351P 2022-04-21 2022-04-21
US63/333,351 2022-04-21
PCT/US2022/075545 WO2023028606A1 (en) 2021-08-27 2022-08-26 Combination therapies

Publications (1)

Publication Number Publication Date
KR20240099142A true KR20240099142A (ko) 2024-06-28

Family

ID=83897998

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247010022A Pending KR20240099142A (ko) 2021-08-27 2022-08-26 병용 요법

Country Status (10)

Country Link
US (1) US20240325530A1 (https=)
EP (1) EP4392137A1 (https=)
JP (1) JP2024532619A (https=)
KR (1) KR20240099142A (https=)
AU (1) AU2022332306A1 (https=)
CA (1) CA3229355A1 (https=)
IL (1) IL310919A (https=)
MX (1) MX2024002467A (https=)
TW (1) TW202323296A (https=)
WO (1) WO2023028606A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021189019A1 (en) 2020-03-20 2021-09-23 Keros Therapeutics, Inc. Activin receptor type ii chimeras and methods of use thereof
WO2021189010A1 (en) 2020-03-20 2021-09-23 Keros Therapeutics, Inc. Methods of using activin receptor type iib variants
PT4408840T (pt) 2021-09-27 2025-10-07 Terns Pharmaceuticals Inc Ácidos benzimidazolocarboxílicos como agonistas de glp-1r
CN118401519A (zh) 2021-10-25 2024-07-26 拓臻制药公司 作为glp-1r激动剂的化合物
TW202339798A (zh) * 2022-01-19 2023-10-16 美商維紗妮絲生物公司 Actrii抗體之治療
CN119095843A (zh) 2022-02-23 2024-12-06 拓臻制药公司 作为glp-1r激动剂的化合物
JP2025529933A (ja) 2022-08-26 2025-09-09 バーサニス・バイオ・インコーポレイテッド ＡｃｔＲＩＩ抗体固定単位用量の治療
EP4568664B1 (en) 2023-04-07 2026-04-01 Terns Pharmaceuticals, Inc. Combination comprising a thr-beta agonist and a glp-1r agonist for use in treating obesity
WO2025027052A1 (en) 2023-07-31 2025-02-06 Sixpeaks Bio Ag Antibody conjugates and fusion proteins
WO2025106773A1 (en) * 2023-11-17 2025-05-22 Apnimed, Inc. (Delaware) Methods and compositions for treating sleep apnea with a combination of a glp-1 agonist and a second active agent
TW202535467A (zh) * 2023-12-29 2025-09-16 大陸商江蘇恆瑞醫藥股份有限公司 抗體－多肽偶聯物及其醫藥用途
WO2025147483A1 (en) * 2024-01-02 2025-07-10 Keros Therapeutics, Inc. Methods of using activin receptor type ii chimeras
WO2025183966A1 (en) 2024-02-28 2025-09-04 Versanis Bio, Inc. Actrii antibodies with extended half life
WO2025217521A1 (en) * 2024-04-12 2025-10-16 Jnana Therapeutics Inc. Treating chronic kidney disease with a combination of a slc6a19 inhibitor and a glp-1 agonist
WO2025247309A1 (zh) * 2024-05-31 2025-12-04 上海齐鲁制药研究中心有限公司 融合蛋白分子及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20120532A1 (es) 2009-04-27 2012-05-18 Novartis Ag ANTICUERPOS ANTI-ActRIIB
JOP20190152A1 (ar) 2016-12-21 2019-06-20 Novartis Ag مضادات الميوستاتين، الآكتيفين أو مستقبلات الآكتيفين للاستخدام في علاج السمنة والحالات ذات الصلة
PT3565592T (pt) * 2017-01-06 2023-05-31 Scholar Rock Inc Tratamento de doenças metabólicas através da inibição da ativação da miostatina

Also Published As

Publication number Publication date
US20240325530A1 (en) 2024-10-03
EP4392137A1 (en) 2024-07-03
IL310919A (en) 2024-04-01
CA3229355A1 (en) 2023-03-02
AU2022332306A1 (en) 2024-02-29
WO2023028606A1 (en) 2023-03-02
MX2024002467A (es) 2024-05-20
JP2024532619A (ja) 2024-09-05
TW202323296A (zh) 2023-06-16

Similar Documents

Publication Publication Date Title
US20240325530A1 (en) Combination therapies
TW201521718A (zh) 低頻率格拉替雷（ｇｌａｔｉｒａｍｅｒ）醋酸鹽之治療
US20240279323A1 (en) Methods for the treatment of scleroderma and related conditions
JP2024521091A (ja) 褐色脂肪生成を誘導する方法及び組成物
AU2020341135A1 (en) Treatment of liver disease or disorder comprising ActRII receptor antagonists
US20260070997A1 (en) Cd40l-specific tn3-derived scaffolds for the treatment and prevention of sjögren's syndrome
JP2025518227A (ja) ｍａｚｄｕｔｉｄｅを使用する治療方法
JP2008518941A (ja) 大腸連続性を伴う短腸症候群患者の治療
US20260070992A1 (en) Actrii antibody fixed unit dose treatments
CN118055767A (zh) 新颖的组合施用
TW202339798A (zh) Actrii抗體之治療
CN118488853A (zh) 组合疗法
WO2025183966A1 (en) Actrii antibodies with extended half life
TW202500575A (zh) 具有或不具有體重相關合併症之過重或肥胖成人之治療
CN118201629A (zh) 用于治疗和预防干燥综合征的cd40l特异性tn3衍生的支架
WO2025157167A1 (zh) 靶向Nectin-4的抗体药物缀合物的用途
CN121969358A (zh) 选择性雄激素受体调节剂（sarm）化合物在长期体重管理中的用途
TW202612733A (zh) 抗ＩＬ－１１Ｒα抗體在治療甲狀腺眼病中之給藥
HK40103690A (zh) 新颖的组合施用
WO2024155810A1 (en) Anti-cd19 binding agents for the treatment and prevention of immune mediated necrotizing myopathy
Miyasaka Etanercept and methotrexate for the treatment of rheumatoid arthritis

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-EXM-PA0201 (AS PROVIDED BY THE NATIONAL OFFICE)

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201